Korbtham Sathirakul

Prof. Korbtham Sathirakul

mahidol university
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2003 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MSMichael H. Skinner
Michael H. Skinner
HKHan‐Yi Kuan
Han‐Yi Kuan
APAlan Pan
Alan Pan
Korbtham SathirakulKorbtham Sathirakul
Korbtham Sathirakul
MKMary Pat Knadler
Mary Pat Knadler
SWStephen D. Wise
Stephen D. Wise
Background and Objectives: Duloxetine, a potent dual reuptake inhibitor of serotonin and norepinephrine currently undergoing clinical investigation for treatment of depression and stress urinary incontinence, has the potential to act as both a substrate and an inhibitor of cytochrome P4502D6 (CYP2D6). Our objectives were to determine the effect of duloxetine on the pharmacokinetics of desipramine, a tricyclic antidepressant metabolized by CYP2D6 (study 1), and the effect of paroxetine, a potent CYP2D6 inhibitor, on duloxetine pharmacokinetics (study 2).Methods: Subjects were healthy men and women between 21 and 63 years old. All subjects were genotypically CYP2D6 extensive metabolizers. In study 1, 50 mg of desipramine was administered as a single dose alone and in the presence of steady‐state duloxetine 60 mg twice daily. In study 2, steady‐state pharmacokinetics of duloxetine 40 mg once daily were determined in the presence and absence of steady‐state paroxetine 20 mg once daily.Results: Duloxetine increased the maximum plasma concentration of desipramine 1.7‐fold and the area under the concentration‐time curve 2.9‐fold. Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration‐time curve at steady state 1.6‐fold. Reports of adverse events were similar whether duloxetine was administered alone or in combination with desipramine or paroxetine.Conclusion: Duloxetine 60 mg twice daily is a moderately potent CYP2D6 inhibitor, intermediate between paroxetine and sertraline. The potent CYP2D6 inhibitor paroxetine has a moderate effect on duloxetine concentrations. The results of these 2 studies suggest that caution should be used when CYP2D6 substrates and inhibitors are coadministered with duloxetine.Clinical Pharmacology & Therapeutics (2003) 73, 170–177; doi: 10.1067/mcp.2003.28

1 April 2015 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
WWWinai Wananukul
Winai Wananukul
STSatariya Trakulsrichai
Satariya Trakulsrichai
Korbtham SathirakulKorbtham Sathirakul
Korbtham Sathirakul
SASaranya Auparakkitanon
Saranya Auparakkitanon
JKJatupon Krongvorakul
Jatupon Krongvorakul
CSChonlaphat Sukasem
Chonlaphat Sukasem
Background: Kratom, known botanically as Mitragyna speciosa (Korth.), is an indigenous tree in Southeast Asia. Kratom is currently easily available worldwide via special shops and the Internet to use as a drug of abuse, opioid alternative, or pain killer. So far, the pharmacokinetics of this plant has been studied only in animals, and there is no such study in humans. The major abundant active alkaloid in Kratom, mitragynine, is one of the promising new chemical substances to be developed as a new drug. The aim of this study was to examine the pharmacokinetics of mitragynine and assess the linearity in pharmacokinetics in chronic users. Methods: Since Kratom is illegal in Thailand, studies in healthy subjects would be unethical. We therefore conducted a prospective study by enrolling ten chronic, regular, healthy users. We adjusted the steady state in each subject by giving a known amount of Kratom tea for 7 days before commencement of the experiment. We admitted and gave different oral doses to subjects to confirm linearity in pharmacokinetics. The mitragynine blood concentrations at 17 times points and the urine concentrations during the 24-hour period were collected and measured by liquid chromatography-tandem mass spectrometry method. Results: Ten male subjects completed the study without adverse reactions. The median duration of abuse was 1.75 years. We analyzed one subject separately due to the abnormal behavior of blood concentration. From data of nine subjects, the pharmacokinetic parameters established were time to reach the maximum plasma concentration (0.83±0.35 hour), terminal half-life (23.24±16.07 hours), and the apparent volume of distribution (38.04±24.32 L/kg). The urine excretion of unchanged form was 0.14%. The pharmacokinetics were observed to be oral two-compartment model. Conclusion: This was the first pharmacokinetic study in humans, which demonstrated linearity and was consistent with the oral two-compartment model with a terminal half-life of about 1 day. The pharmacokinetic linearity and parameters reported are necessary pharmacological information of Kratom, and there is a possibility for it to be developed medically as a pain killer or better opioid substitute in the future.

1 April 2018 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
CSC. Siangsanoh
C. Siangsanoh
SUS. Ummartyotin
S. Ummartyotin
Korbtham SathirakulKorbtham Sathirakul
Korbtham Sathirakul
PRP. Rojanapanthu
P. Rojanapanthu
WTW. Treesuppharat
W. Treesuppharat

1 June 1993 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
Korbtham SathirakulKorbtham Sathirakul
Korbtham Sathirakul
HSH Suzuki
H Suzuki
KYK Yasuda
K Yasuda
MHM Hanano
M Hanano
OTO Tagaya
O Tagaya
YSY Sugiyama
Y Sugiyama

1 May 1998 in Robotica
Verified
Journal Article
Closed access
PDF file
Korbtham SathirakulKorbtham Sathirakul
Korbtham Sathirakul
RSRobert H. Sturges
Robert H. Sturges
Reliable flexible assembly workstations depend ultimately on the physics of assembly tasks performed. Multiple-peg insertions, as a practical assembly class, is complicated by the large number and kind of interaction between mating parts.In this article, geometric and quasi-static analyses of multiple-peg insertions are presented. First, a possible contact-state enumeration, geometric conditions for each contact-state, and the force-moment equations for static-equilibrium states of two dimensional dual-peg insertions are derived. The jamming diagrams and the taxonomy of dual-peg insertions are obtained. Then, an experiment to verify the analysis is presented.

1 June 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Thitianan KulsiriratThitianan Kulsirirat
Thitianan Kulsirirat
Korbtham SathirakulKorbtham Sathirakul
Korbtham Sathirakul
NKNoriyasu Kamei
Noriyasu Kamei
MTMariko Takeda-Morishita
Mariko Takeda-Morishita